Hylaform approved for wrinkles
This article was originally published in The Gray Sheet
Executive Summary
Inamed will commence shipments "immediately" of the Genzyme-made hyaluronic acid dermal filler under a marketing agreement. PMA approval announced April 22 does not require a pre-treatment skin test, Inamed notes. The product will be priced competitively with rival Medicis' filler Restylane, approved in December (1"The Gray Sheet" Dec. 15, 2003, In Brief). Both fillers received approvable-with-conditions recommendations from FDA's General & Plastic Surgery Devices Panel in November (2"The Gray Sheet" Dec. 1, 2003, p. 12)...
You may also be interested in...
Inamed v. Medicis
Restylane hyaluronic acid dermal filler marketer Medicis will challenge the validity of competitor Inamed's U.S. patent 4,803,075 in response to an infringement action brought by Inamed in San Diego federal court against Medicis and Restylane manufacturer Q-Med. The device was approved last December, four months ahead of Inamed's Hylaform (1"The Gray Sheet" April 26, 2004, In Brief). The patent covers use of a lubricant in dermal fillers to ease injection. Medicis notes that Inamed also is seeking a U.S. International Trade Commission investigation related to the alleged infringement. Medicis believes it has "meritorious defenses," maintaining that Q-Med cited the patent as prior art in its PMA application...
Restylane approval
Q-Med's hyaluronic acid-based facial wrinkle treatment earns marketing go-ahead Dec. 12, just 21 days after FDA's General & Plastic Surgery Devices Panel endorsed the device in a 6-3 vote. Marketing partner Medicis has increased its sales force for imminent launch (1"The Gray Sheet" Sept. 8, 2003, p. 19). Rival HA filler Hylaform, marketed by Inamed and manufactured by Genzyme, is awaiting a decision from FDA. The two dermal filler PMAs shared a Nov. 21 panel date...
Facial Implant Panel Endorsement Masks Study Bias Concerns
Potential biases resulting from the use of patients as their own controls within Q-Med's Restylane pivotal trial drew criticism during FDA panel review of the hyaluronic acid-based dermal filler Nov. 21